Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025. The company's ...

TOKYO, January 31, 2025--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025 ...

Hiroyuki Okuzawa, CEO of Japanese pharmaceutical giant Daiichi Sankyo, talks about the company's revenue driver in its latest report, and the lack of visibility from the impact of potential U.S ...

Hiroyuki Okuzawa. Well, I can't really tell you one way or the other. But during the fifth wave, it's true that there were many situations where it was used for such side reactions.

Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sunao Manabe, DVM, PhD, will continue to serve as representative director and ...

RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform (Norio Hamamatsu, President and CEO) ...

"A good drug brings solutions to business,” President Hiroyuki Okuzawa said in an interview. "Enhertu helped us raise our profile, attract world class talent and boosted our capability in oncology.

Okuzawa has 50,741 shares of the company as of September 30, 2024. “ Hiroyuki Okuzawa has played a pivotal role in advancing our current five-year business plan, driving unprecedented global ...

Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025. The company's board of directors followed the nomination committee's report, ...

Okuzawa graduated from Hitotsubashi University in Tokyo with a degree in Social Sciences. Okuzawa has 50,741 shares of the company as of September 30, 2024. “Hiroyuki Okuzawa has played a pivotal role ...

TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective ...